European surveillance of immunoglobulin safety - Results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries
European surveillance of immunoglobulin safety - Results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries
复制标题
DOI：
10.1006/clim.2002.5239
复制
发表时间：
2002-09-01
影响因子：
8.6
通讯作者：
Aiuti, F
中科院分区：
文献类型：
--
作者：
Quinti, I;Pierdominici, M;Aiuti, F
进行了一项欧洲多中心研究，以获得有关免疫球蛋白给药的现行做法、用于监测丙型肝炎病毒（HCV）传播风险的政策以及低丙种球蛋白血症患者HCV感染自然史的信息。来自16个国家的1243例原发性免疫缺陷患者的数据表明，90%的抗体缺陷患者在住院期间接受静脉注射免疫球蛋白，7%的患者主要在家中接受皮下注射免疫球蛋白治疗。据报告，为监测病毒性肝炎传播风险而监测的检测频率和类型存在很大差异。只有60%的患者至少接受过一次HCV RNA检测。来自71例HCV感染患者的数据表明，约40%的患者的HCV感染进展迅速，伴有终末期肝病。10%的患者自发清除病毒，约30%无症状。CVID患者的预后比XLA患者差。(C)2002 Elsevier Science（美国）。
A European multicenter study was conducted to obtain information on the current practices of immunoglobulin administration, the policies in use for the surveillance of the risk of hepatitis C virus (HCV) transmission, and the natural history of HCV infection in patients with hypogammaglobulinemia. Data from 1243 patients with primary immunodeficiencies in 16 countries demonstrated that 90% of patients with antibody deficiencies receive intravenous immunoglobulins in an inpatient setting, and 7% of patients are treated with subcutaneous immunoglobulins, mainly at home. Wide variations have been reported regarding the frequency and the type of tests monitored for the surveillance on the risk of viral hepatitis transmission. Only 60% of patients have been tested at least once for HCV RNA detection. Data from 71 HCV-infected patients demonstrated a rapid progression of HCV infection, with end-stage liver disease, in about 40% of patients. Ten percent of patients spontaneously cleared the virus, and about 30% are asymptomatic. Patients with CVID have a worse prognosis than patients with XLA. (C) 2002 Elsevier Science (USA).